LOGIN  |  REGISTER
Assertio
Astria Therapeutics

Rockwell Medical Named 'Great Place to Work' for Second Year in a Row

March 25, 2024 | Last Trade: US$2.25 0.05 2.27

WIXOM, Mich. / Mar 25, 2024 / Business Wire / Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has been certified as a Great Place to Work® for the second year in a row.

"We are proud to be named a 'Great Place to Work' for the second year in a row," said Lesley Spriggs, Vice President of Human Resources at Rockwell Medical. "This accreditation is a genuine reflection of how our employees feel about their experiences working at Rockwell, where we encourage and foster authenticity, trust, leadership and innovation. Year-over-year, we have implemented a number of positive changes across the organization. We have made tremendous progress unifying our teams and ensuring that they know how much we value their contributions and the positive impact what they do every day has on patients suffering from end stage kidney disease."

We're Hiring!

Looking to grow your career at a company that puts its people first? Visit our Career Page at: www.rockwellmed.com/Careers.

About Great Place to Work®

Great Place to Work® ("GPTW") is the global authority on workplace culture. Great Place to Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve, is recognized worldwide by employees and employers alike, and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get GPTW Certified. GPTW Certification is the only recognition based entirely on what employees report about their workplace experience—specifically, how consistently they experience a high-trust workplace. Learn more at greatplacetowork.com.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of hemodialysis concentrates. Certified as a Great Place to Work® in 2023 and 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.RockwellMed.com.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB